Breast Cancer
Conference Coverage
Nothing to gain from chemo after pCR achieved
SAN ANTONIO - The only thing women with localized breast cancer who achieve a pCR after neoadjuvant chemo may gain from further chemo from...
Conference Coverage
Small absolute difference between partial and whole breast irradiation
SAN ANTONIO – A phase 3 trial was unable to rule out the possibility that, after lumpectomy, partial breast irradiation is inferior to whole...
Latest News
Low-dose tamoxifen halves recurrence of breast intraepithelial neoplasia
SAN ANTONIO – Women with breast intraepithelial neoplasms who took tamoxifen for 3 years at a dose of 5 mg per day had a 50% reduction in risk of...
Conference Coverage
Adjuvant capecitabine found disappointing in TNBC
SAN ANTONIO – A phase 3 trial was negative, showing that adding adjuvant capecitabine to surgery and chemotherapy does not improve survival in...
Conference Coverage
Adjuvant T-DM1 halves HER2-positive invasive breast cancer recurrence
SAN ANTONIO – The 3-year invasive disease-free recurrence was 88.3% for patients with residual disease treated with T-DM1 versus 77.0% with...
Feature
Trio of biosimilars have good showing
Case Reports
Elevated liver function tests in a patient on palbociclib and fulvestrant
Original Report
Symptom burdens related to chemotherapy-induced anemia in stage IV cancer
Conference Coverage
PD-L1 expression best predicts response to atezolizumab + nab-paclitaxel for mTNBC
SAN ANTONIO – IMpassion130 analyses show that PD-L1 expression on tumor-infiltrating immune cells is the best...
Conference Coverage
No boost in OS with addition of capecitabine for early TNBC
SAN ANTONIO – Adding adjuvant capecitabine to surgery and standard chemotherapy did not improve disease-free or overall survival in women with...
Conference Coverage
Similarity of CT-P6 and trastuzumab remain with longer follow-up
The efficacy and cardiac toxicity profile between trastuzumab biosimilar candidate CT-P6 and trastuzumab, as neoadjuvant and then adjuvant therapy...